Glycosylation inhibitors block the expression of LAV/HTLV-III (HIV) glycoproteins

Biochem Biophys Res Commun. 1986 Nov 26;141(1):33-8. doi: 10.1016/s0006-291x(86)80330-8.

Abstract

The glycosylation inhibitors 2-deoxy-D-glucose (2-dGlc) and, to a lesser extent, beta-hydroxynorvaline blocked the formation of syncytia in HIV (LAV/HTLV-III)-infected cells. Using monospecific polyclonal antibodies against recombinant envelope proteins gp110 and gp41 or monoclonal antibodies against env gp110, we could demonstrate a marked reduction in the immunoreactivity of these antigens in HIV-infected cells exposed to the glycosylation inhibitors. There was concomitant accumulation of core proteins p15 and p24, as shown by a solid phase radio-immunoassay, and a decreased oligosaccharide synthesis of env proteins, as monitored by the incorporation of [6-3H]GlcNAc. The reverse transcriptase was not affected by the compounds. Glycosylation inhibitors may be considered for the chemotherapy of AIDS or AIDS-related complex, or chemoprophylaxis of HIV-positive individuals.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Deoxy Sugars / pharmacology*
  • Deoxyglucose / pharmacology*
  • Glycosylation
  • HIV / drug effects
  • HIV / metabolism*
  • Protein Processing, Post-Translational / drug effects
  • Radioimmunoassay
  • Threonine / analogs & derivatives*
  • Threonine / pharmacology
  • Viral Core Proteins / metabolism
  • Viral Envelope Proteins / immunology
  • Viral Envelope Proteins / metabolism*
  • Virus Replication / drug effects

Substances

  • Deoxy Sugars
  • Viral Core Proteins
  • Viral Envelope Proteins
  • 3-hydroxynorvaline
  • Threonine
  • Deoxyglucose